T. Rowe Price Associates
FHTX icon

T. Rowe Price Associates’s Foghorn Therapeutics FHTX Stock Holding History

T. Rowe Price Associates’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$120K Hold
24,478
– – ﹤0.01% 3119
2026
Q1 		$118K Buy
24,478
+8,070
+49% +$44.3K ﹤0.01% 2961
2025
Q4 		$89K Hold
16,408
– – ﹤0.01% 2964
2025
Q3 		$81K Buy
16,408
+2,161
+15% +$11.5K ﹤0.01% 2960
2025
Q2 		$67K Buy
+14,247
New +$59.5K ﹤0.01% 2962

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

T. Rowe Price Associates's FHTX Position: Q2 2026 in Review

T. Rowe Price Associates held its Foghorn Therapeutics (FHTX) position steady in Q2 2026 at 24,478 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #3119.

T. Rowe Price Associates first reported a position in FHTX in Q2 2025 and has held it in 5 quarters since. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • T. Rowe Price Associates held 24,478 shares of Foghorn Therapeutics worth $120K as of Q2 2026.
  • T. Rowe Price Associates left its Foghorn Therapeutics share count unchanged in Q2 2026.
  • Foghorn Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3119 holding.
  • T. Rowe Price Associates first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.